A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

Launched by NOVO NORDISK A/S · Jun 1, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called CagriSema to see how well it helps people with obesity lose weight and keep that weight off over the long term. The trial has two parts: the main study and an extension study. In the main study, participants will receive either CagriSema or a placebo (which is a dummy medicine with no active ingredients). The participants have a better chance of receiving CagriSema than the placebo. After the main study, those who received CagriSema will continue with the same medication, while those who received the placebo will switch to CagriSema in the extension study. Participants will take one injection once a week for about 3 years and 3 months.

To take part in this trial, individuals must be at least 18 years old and have a body mass index (BMI) of 30 or higher, which indicates obesity. They should also want to lose at least 25% of their body weight over about 80 weeks. However, people with certain health conditions, like diabetes, cannot join the study. Overall, this trial aims to provide valuable information on how effective CagriSema is for helping people manage their weight.

Gender

ALL

Eligibility criteria

• key Inclusion Criteria:
• • Male or female (sex at birth).
• • Age 18 years or above at the time of signing the informed consent.
• • BMI ≥ 30.0 kilogram per square meter (kg/m\^2) at screening.
• • Participant has a wish to lose at least 25% of body weight within 80 weeks from randomisation.
• key Exclusion Criteria:
• • Glycated haemoglobin (HbA1c) ≥ 6.5% (48 millimole per mole \[mmol/mol\]) as measured by the central laboratory at screening.
• • History of type 1 or type 2 diabetes.